ulobetasol propionate (Ultravate) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG PubChem

Active Ingredient History

NOW
  • Now
Ulobetasol propionate, also known as halobetasol propionate and sold under the brand name Ultravate among others, is a synthetic glucocorticoid corticosteroid and a corticosteroid ester.   Wikipedia

Chemistry

  • SMILES: CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl
  • InChIKey: BDSYKGHYMJNPAB-LICBFIPMSA-N
  • Mol. Mass: 484.97
  • ALogP: 4.05
  • ChEMBL Molecule:
    halobetasol propionate  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Topical
  • Pro Drug: Yes

Alternative names

000-0551 | halobetasol propionate | idp-118 | miracorten | ulobetasol propionate

Organizations (16)

Research & Development (4)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (14)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (3)

Approved Indications (1)


 

Psoriasis (approved 1990)

Experimental Indications - Clinical Trial Phases 1-4 (3)


 

Acne Keloid (Phase 3)

Acne Vulgaris (Phase 3)

Psoriasis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 10
  • # of Trial Organizations: 4

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue